Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease
Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease
Prime Medicine 公布的临床前数据表明 PM359 能够高效、可重复和持久地纠正慢性肉芽肿病的致病突变
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected
研究结果表明，PM359 能够纠正 CGD 患者血液干细胞中的致病突变，从而在未检测到脱靶编辑的情况下恢复体内免疫功能
IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial
美国食品药品管理局最近批准了 PM359 的临床试验；数据支持进入第 1/2 期临床试验
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be...
马萨诸塞州剑桥，2024年5月8日（GLOBE NEWSWIRE）——致力于提供新一类差异化的一次性治疗基因疗法的...
登录免费看全文
登录/注册